Overview

Estrogen, HDL, and Coronary Heart Disease in Women

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tufts University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Estrogens
Estrogens, Conjugated (USP)
Medroxyprogesterone
Medroxyprogesterone Acetate